Results 1 to 10 of about 1,147 (134)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context [PDF]

Biomedicines, 2021
Dalbavancin is a lipoglycopeptide approved for treatment of Gram-positive infections of skin and skin-associated structures (ABSSSI). Currently, off-label use at high dosages for osteoarticular infections deserves attention.
Amedeo De Nicolò, Giacomo Stroffolini, Miriam Antonucci, Jacopo Mula, Elisa Delia De Vivo, Jessica Cusato, Alice Palermiti, Giuseppe Cariti, Giovanni Di Perri, Silvia Corcione, Francesco Giuseppe De Rosa, Antonio D’Avolio   +11 more
doaj   +3 more sources

Using Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients: A Real-Life, Single-Center Observational Study [PDF]

Antibiotics
Background/Objectives: Obesity is an established risk factor for several infective conditions, including Acute Bacterial Skin and Skin Structure Infections (ABSSSIs), with a rising trend in their incidence expected in this population.
Alessandra Oliva, Flavia Petrucci, Cristiana Leanza, Marco Rivano Capparuccia, Michela Comi, Claudio Mastroianni   +5 more
doaj   +2 more sources

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis [PDF]

BMC Infectious Diseases
Background Few studies have compared the efficacy and safety of omadacycline with other treatments for acute bacterial skin and skin structure infections (ABSSSI). Therefore, updated meta-analyses on this topic is necessary.
Wen-qiang Kong, Yun-feng Shu , Juan Tang, Shi-qin Li, Hong Zhong, Xuan-yi Zhang   +5 more
doaj   +2 more sources

Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia

Global & Regional Health Technology Assessment, 2020
Introduction: Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) include all complicated skin and soft tissue infections. The aim of this study was to conduct a cost-utility analysis to compare dalbavancin with standard antibiotic therapies for
Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Rosario Cultrera, Francesco Saverio Mennini   +4 more
doaj   +5 more sources

Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections [PDF]

Global & Regional Health Technology Assessment
Introduction: Inpatient treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) involves a significant economic burden on the healthcare system.
Matteo Scortichini, Alessandro Ruggieri, Agnese Cattaneo, Patrizia Mascagni, Paolo Sciattella   +4 more
doaj   +2 more sources

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Therapeutics and Clinical Risk Management, 2016
Kimberly D Leuthner,1 Kristin A Buechler,1 David Kogan,1 Agafe Saguros,1 H Stephen Lee2 1Department of Pharmaceutical Services, University Medical Center of Southern Nevada, Las Vegas, NV, USA; 2Roseman University of Health Sciences College of Pharmacy,
Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS   +4 more
doaj   +4 more sources

Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS Trials [PDF]

Infectious Diseases and Therapy
Introduction Appropriate oral antibiotic therapy for the treatment of acute bacterial skin and skin structure infections (ABSSSI) is a challenge, as current oral treatment guidelines do not fully cover the most common skin pathogens.
George D. Rodriguez, Nathan Warren, Roman Yashayev, Surya Chitra, Maria Amodio-Groton, Kelly Wright   +5 more
doaj   +2 more sources

Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series. [PDF]

Infez Med
Acute bacterial skin and skin-structure infections (ABSSSI) are a significant cause of morbidity in pediatric patients, requiring timely and effective treatment. Dalbavancin, a long-acting lipoglycopeptide antibiotic recently approved for pediatric use, offers advantages such as excellent bactericidal activity against Gram-positive bacteria (including ...
Garbo V, Condemi A, Albano C, Polara VF, Parrino R, Macaluso A, Venuti L, Colomba C.   +7 more
europepmc   +3 more sources

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center

Antibiotics, 2021
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of ...
Lucia Brescini, Filippo Della Martera, Gianluca Morroni, Sara Mazzanti, Maria Di Pietrantonio, Paolo Mantini, Bianca Candelaresi, Francesco Pallotta, Silvia Olivieri, Valentina Iencinella, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Salvatore Veccia, Oscar Cirioni, Marcello Tavio, Andrea Giacometti   +16 more
doaj   +1 more source

The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) [PDF]

Expert Review of Anti-infective Therapy, 2020
Introduction: Acute bacterial skin and skin-structure infections (ABSSSI) are a subgroup of skin and soft tissue infections and are a common source of morbidity in both the community and the hospital setting. The most common cause of ABSSSI is Staphylococcus aureus, which also includes methicillin-resistant S.
Alex Soriano, Gian Maria Rossolini, Federico Pea   +2 more
openaire   +4 more sources